Dr. Ailawadhi on the Rationale for Evaluating Lisaftoclax in CLL


In Partnership With:

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Sikander Ailawadhi, MD, professor of medicine, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, lead, International Cancer Center, Mayo Clinic, discusses the rationale for evaluating lisaftoclax (APG-2575) in chronic lymphocytic leukemia (CLL) in an early phase 1 study (NCT03537482).

Venetoclax (Venclexta), a first-generation BCL-2 inhibitor, is FDA approved for the treatment of several lymphoid and myeloid malignancies, including CLL.The rationale for the phase 1 trial was to continue exploring the role of BCL-2 inhibitors in CLL with the next-generation agent lisaftoclax, Ailawadhi explains. Lisaftoclax was hypothesized to be more refined, more active, and better tolerated compared with venetoclax in this patient population, Ailawadhi says. 

Lisaftoclax has a distinct pharmacokinetic and pharmacodynamic profile in which it affects but does not irreversibly bind to BCL-2 to cause prolonged adverse effects, Ailawadhi adds. Overall, lisaftoclax demonstrated similarefficacy to venetoclax with a different, safer toxicity profile, Ailawadhi concludes.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine